A multiple sclerosis (MS) treatment reduced a common painful side effect of Velcade (bortezomib) in a mouse model, suggesting that it might help…
Myeloma
Myeloma is a rare blood cancer that begins in plasma cells, a type of white blood cell normally responsible for producing antibodies that help fight off infectious pathogens and other threats.
While myeloma treatment can drive the disease into remission, sometimes for long periods of time, the cancer will often come back after a few months or years, and additional treatments will be needed.
Latest news
Celgene’s investigational and second-generation CAR T-cell therapy bb2121 is showing real promise in treating advanced multiple myeloma patients, those with relapsed or refractory disease, updated…
The University of Alabama at Birmingham (UAB) is recruiting patients with newly diagnosed multiple myeloma for a Phase 2 trial evaluating an…
The investigational cancer vaccine galinpepimut-S (GPS) has been designated an orphan drug by the U.S. Food and Drug Administration as a possible treatment of…
The U.S. Food and Drug Administration (FDA) has approved Darzalex (daratumumab) in combination with standard therapy for the treatment of patients with newly-diagnosed multiple myeloma who…
A quarter of heavily treated patients with penta-refractory multiple myeloma responded to Karyopharm‘s investigative oral therapy selinexor (KPT-330), according to top-line data from…
